Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Obeticholic acid for non-alcoholic steatohepatitis and fibrosis	Obeticholic Acid (Ocaliva; INT-747)	Non-alcoholic steatohepatitis (NASH)	Hepatology	2019	View \| Download
Obecabtagene autoleucel for treating refractory or relapsed B cell acute lymphoblastic leukaemia	Obecabtagene autoleucel	Acute lymphoblastic leukaemia (ALL)	Haematological Cancer and Lymphomas	2023	View \| Download
NY-ESO-1 T cells for the treatment of synovial sarcoma	NY-ESO-1c259-modified SPEAR T Cells (GSK3377794)	Soft tissue sarcoma	Sarcoma	2017	View \| Download
NVK-002 for myopia in children	NVK-002	Myopia	Ophthalmology	2023	View \| Download
NPJ5008 for treating malignant hyperthermia	NPJ5008	Malignant hyperthermia	Genetic Disorders	2022	View \| Download
NOVOCART 3D for articular cartilage defects of the knee	Autologous Chondrocyte Implant (NOVOCART 3D)	Articular cartilage defects	Musculoskeletal System	2019	View \| Download
Nivolumab-relatlimab adjuvant therapy for stage III-IV resected melanoma	Nivolumab-relatlimab	Melanoma	Skin Cancer	2024	View \| Download
Nivolumab-ipilimumab for previously untreated advanced hepatocellular carcinoma	Nivolumab-ipilimumab	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2022	View \| Download
Nivolumab with ipilimumab for previously untreated locally advanced non-small-cell lung cancer	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Nivolumab with ipilimumab adjuvant therapy for renal cell carcinoma	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2022	View \| Download